USAID has just awarded $160 million to the United States Pharmacopeia (USP) for a cooperative agreement to regulate the pharmaceutical landscape in Africa. U.S. taxpayers are now funding a U.S. State Department approved plan developed so our government can help big pharma pimps. Here’s a look inside USP and this latest USAID plan.
If you scan the Board of Trustees of the NGO USP you will immediately run into BIG BUSINESS shining like the sleazy glow from some red-light district brothel in Paris or New Orleans. Aventis, Bristol-Myers Squibb Company, India’s Laurus Labs, Eli Lilly & Company, Pfizer, Pharmacia, Upjohn, France’s Sanofi, and all the likely suspects are proudly listed in plain sight. The agri-giants are there too, smiling out at you like comic book villains from DC or Marvel. There’s FSG consulting executives proud to have been solving the world’s problems since the Soviet Union fell. FDA Chief Scientists are listed, and so are Washington regulatory specialists (and lobbyists) representing firms like Greenleaf Health Inc.
Ronald T. Piervincenzi, Ph.D., the CEO of USP could serve as the poster boy for big pharma and big Agra businesses. Ronald’s major in college way biomedical engineering. Ronald now sets the standards for most every medication sold in the United States. He got his start at Hofstra University on Long Island and from visits to the Naval Research Laboratory in Washington DC. He went to Duke University and got a “magical” full-time position with McKinsey & Company. You can read the rest of “Ron Piervincenzi: A Series of Fortunate Events” here.
You can see Ron here in Nigeria alongside USAID in Nigeria when the National Agency for Food and Drug Administration and Control (NAFDAC) Kaduna laboratory was accreditated in 2017. At first glance, USP and USAID efforts appear viable, straightforward, and even altruistic and noble. This is from the press release on the most recent USAID-USP effort in Africa:
“To achieve the goal of PQM+, USP and its partners will work to strengthen governance and regulatory structures, optimize the allocation and use of resources, improve the supply of quality-assured medical products….”
USP and USAID capitalize on the problems of bad or illegitimate drugs administered for tough diseases like malaria.